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Neuronal functionAlzheimer's disease is the most common neurodegenerative disorder. Although lipids are major constituents
of brain, their role in Alzheimer's disease pathogenesis is poorly understood. Much attention has been given
to cholesterol, but growing evidence suggests that other lipids, such as phospholipids, might play an
important role in this disorder. In this review, we will summarize the evidence linking phospholipase D, a
phosphatidic acid-synthesizing enzyme, to multiple aspects of normal brain function and to Alzheimer's
disease. The role of phospholipase D in signaling mechanisms downstream of beta-amyloid as well as in the
trafficking and processing of amyloid precursor protein will be emphasized.dical Center, Department of
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Alzheimer's disease (AD) is a neurodegenerative disease charac-
terized clinically by progressive memory deficits, impaired cognitive
function, altered and inappropriate behavior, and a decline in
language function [1–3]. AD patients display cortical atrophy, loss of
neurons and synapses, as well as extracellular senile plaques and
intracellular neurofibrillary tangles (NFTs). While senile plaques are
largely composed of aggregated amyloid β-peptide (Aβ) [1,2], tangles
consist of pairs of ∼10 nm filaments wound into helices, also called
paired helical filaments, and contain hyperphosphorylated forms of
the microtubule-associated protein tau (MAPT). Growing evidence
indicates that there is crosstalk between Aβ and tau pathogenesis [4].
Genetic studies of families with AD have identified several genes that
are important in the pathogenesis of AD. The most widely studied
mutations occur in three genes: β-amyloid precursor protein (APP),
presenilin 1 (PS1) and presenilin 2 (PS2). APP is the precursor protein
of Aβ, and the presenilins have been identified as components of the
γ-secretase complex, which, alongside the β-secretase, are responsi-
ble for the generation of Aβ [1,2].
Aβ is derived from the sequential cleavage of type I transmem-
brane protein APP by membrane-bound proteases, β- and γ-secretase
[1,5,6]. Beta-site APP cleavage enzyme 1 (BACE1) has been identified
as the major β-secretase activity that mediates the first cleavage ofAPP in the β-amyloidogenic pathway [7,8]. BACE1-mediated cleavage
leads to the release of the APP ectodomain sAPPβ into the
extracellular space. The remaining COOH-terminal fragment (CTF),
which can be either 99 or 89 amino acids in length (termed “C99” or
“C89”), undergoes subsequent cleavage by γ-secretase to release Aβ
and the APP intracellular COOH-terminal domain (AICD). The
presenilins have been proposed to be the major catalytic component
of the γ-secretase complex, whose sequential intramembrane
cleavage of APP produces a spectrum of Aβ peptides varying in length
by a few amino acids at the COOH-terminus [5,7]. The majority of Aβ
normally ends at amino acid 40 (Aβ40), but the 42-amino acid variant
(Aβ42) is more amyloidogenic, and has been hypothesized to
nucleate senile plaque formation [1,5,7]. In the past few years it has
been shown that soluble oligomeric Aβ40/42 in various assembly
states better correlate with synaptic malfunction and cognitive
impairment than neuritic plaques in vivo, consistent with mounting
evidence that oligomeric Aβ is significantly synaptotoxic [1].
As mentioned above, a number of links exist between Aβ and tau
pathologies. Importantly, in an AD mouse model associated with a
significant Aβ burden, the genetic ablation of tau was neuroprotective
forAβ-induceddeficits [9], supportingan intimate crosstalk betweenAβ
and tau. However, it is not clear whether the precise reasons for the
protective role(s) of tau ablation are related directly to tau's pathogenic
potential. Overall, this relationship between the two major pathogenic
AD hallmarks remains poorly understood [4]. Nevertheless, develop-
ment of an improved understanding of tau-related pathology may
inform not only our knowledge of Aβ-related dysfunction in AD but the
illness as a whole.While no familial genetic studies have shown a direct
cause effect for tau mutations in AD, mutations in the MAPT gene were
shown to cause a distinct neurodegenerative disorder, frontal temporal
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MAPT gene, which, through alternative splicing, can lead to the
expression of six different isoforms in the human brain. MAP tau has a
well-established known function of stabilizing microtubules. The
microtubule-binding capacity of tau is known to be regulated by post-
translational modifications. The most well established process is
phosphorylation, mediated by a number of kinases including glygogen
synthase kinase 3 (GSK3), cyclin-dependent kinase 5 (CDK5) and
microtubule-affinity-regulating kinase (MARK). Additionally, oxidative
stress has been suggested to play a role in tau modifications. The
formation of NFTs is thought to be a sequential process that starts with
impaired tau phosphorylation, detachment of tau from microtubules,
accumulation ofmisfolded tau, tau aggregation in pretangles, formation
of paired helical filaments and finally NFTs [10].
2. Phospholipid imbalance in Alzheimer's disease
Lipid-mediated signaling regulates a plethora of physiological
processes, including multiple aspects of brain function. Dysregulation
of lipid pathways has been involved in a growing number of
neurodegenerative disorders. While much attention has been given
to the sterol link to AD [11], growing evidence, suggests that other
classes of lipids, such as phospholipids, either mediate or modulate
key pathological processes associated with AD [12–14]. The first
studies to address these questions were based on post-mortem lipid
analysis of brain tissue from AD-affected individuals. For instance, it
was reported that anterior temporal cortex of brains from patients
with AD had significantly lower levels of phosphatidylinositol (PI) and
trends for lower levels of PI phosphate (PIP) and PI-4,5-bisphosphate
[PI(4,5)P2] [15], a major signaling lipid regulating a variety of
biological processes at the plasma membrane and whose normal
balance is required for proper synaptic function [16]. Nitsch et al. [17]
observed that brains of AD patients had decreased levels of
phosphatidylcholine (PC) and phosphatidylethanolamine (PE), pro-
posing that AD may be associated with increased membrane
phospholipid degradation. Furthermore, using 31P Nuclear Magnetic
Resonance to study AD brain preparations, a significant reduction in
PE and PI levels was observed, with a trend for a decrease in PC,
phosphatidic acid (PA) and cardiolipin and an increase in sphingo-
myelin and the plasmalogen derivative of PE [18].
The interaction of both tau and Aβ with cellular and artificial
membranes has been extensively investigated. Given direct binding of
tau to membrane phospholipids, it was hypothesized that this
interaction may be relevant for the physiological function of tau as
well as AD pathogenesis [19]. Similarly, Aβ can directly alter artificial
lipid bilayers by forming pores that are permeable to various ions [20].
Moreover, an in vitro study showed that Aβ disrupts membranes
containing acidic phospholipids in a pH-dependent way with more
pronounced effects on membranes at acidic pH [21]. More recently,
after the discovery of the synaptotoxic properties of soluble Aβ
oligomers, studies showed that these oligomers destabilize mem-
branes and trigger Ca2+ influxes through unknown mechanisms [22].
In part reflecting the pathophysiological relevance of oligomer-
induced Ca2+ dyshomeostasis, acute and chronic treatments of
neurons with soluble oligomers of Aβ were shown to disrupt the
metabolism of PI(4,5)P2 in a phenomenon requiring both extracellular
Ca2+ and PLC activity [13]. Consistent with the view that PI(4,5)P2
destabilization plays a key role in the synapse-impairing actions of Aβ
oligomers, hippocampal slices derived from a genetic model lacking
one copy of Synj1 (i.e., a gene encoding the PtdIns(4,5)P2 phosphatase
synaptojanin) exhibit normal PtdIns(4,5)P2 levels and long-term
potentiation (LTP) despite the presence of Aβ42 oligomers [13].
Similarly, a recent study showed that dysregulation of the group IV A
phospholipase A2 pathway mediates some aspects of synaptic and
neurobehavioral dysfunction in a mouse model of AD [14]. These two
studies provide further support to a prior hypothesis maintaining thatphospholipases are highly dysregulated in AD [23]. FAD mutations of
presenilins were also shown to cause an imbalance in the metabolism
of PI(4,5)P2 and that correcting this imbalance decreased amyloido-
genesis [12].
Given the body of evidence presented above demonstrating the
importance of phospholipids and AD, development of an improved
understanding of phospholipid signaling is essential. Increasing
evidence has pointed to one enzyme family especially in regulating
biosynthesis and metabolism of phospholipids: phospholipase D
(PLD). In this review, we will address the role of the PLD pathway
in brain regulation as well as discuss its potential implication in AD.
3. Overview of PLD—structure, function and localization
The first evidence for PLD-like activity was reported in plants in
1947 [24], while a mammalian PLD activity was described for the first
time in 1973 in rat brain extracts [25]. However, two decades passed
until the purification [26] and cloning [27] of PLD from plants. This
subsequently led to the identification of SPO14 as a gene that is
essential for meiosis and sporulation in yeast and encodes an enzyme
harboring PLD activity [28]. The availability of DNA sequences led to
the cloning of two PLD isozymes in mammals, PLD1 [29] and PLD2
[30,31]. In mammals there are three validated isozymes of PLD: PLD1,
PLD2 and the recently-identified mitochondrion-associated mitoPLD
[32–34]. Themajority of studies have so far focused on PLD1 and PLD2
(Fig. 1a), which share: (i) two HxKxxxxD (HKD) motifs that are
essential for catalysis; (ii) a phox (PX) consensus sequence and (iii) a
pleckstrin homology (PH) domain, which are phosphoinositide-
binding modules that are required for proper targeting of PLD; and
(iv) a PIP2-binding site, which is fundamental for the enzymatic
activity. However, PLD1 differs from PLD2 by the presence of a loop
region, which has been proposed to function as a negative regulatory
element for catalysis (Fig. 1a) [32]. In the presence of water, both PLD1
and -2 hydrolyze phosphatidylcholine (PC) to generate phosphatidic
acid (PA) and free choline. However in the presence of primary
alcohols, such as ethanol and 1-butanol, PLD preferentially (∼1000-
fold) uses these nucleophiles over water for the transphosphatidyla-
tion reaction, thus leading to the formation of non-naturally occurring
phospholipids, phosphatidylethanol (PtdEtOH) or phosphatidylbuta-
nol (PtdBut), respectively [35] (Fig. 1c). This atypical property of the
enzyme has been exploited in a myriad of studies either to block the
production of bioactive lipid PA or to measure PLD activity in intact
cells or tissues.
PA has unique bioactive properties and can modify both the
physical and signalling properties of lipid bilayers. Structurally, it is
composed of a three-carbon glycerol backbone, two fatty acid chains
and a small phosphate headgroup, thus referred to as a “cone shape”
lipid (i.e., a lipid with a small head groups relative to a large
hydrophobic domain) [32,36]. This property not only confers PA a
higher affinity for negative curvature within lipid bilayers, but it also
reduces the energy barrier for bending membrane, thus acting as a
fusogenic lipid. Somewhat reminiscent of phosphoinositides, PA also
plays an important role at the membrane-cytosol interface through a
direct interaction with effector proteins, such as PIP kinases, mTOR,
SNARE proteins and sphingosine kinase [37]. However, unlike a
variety of phosphoinositide-binding modules (e.g., pleckstrin homol-
ogy or FYVE domains), PA-binding (poly)peptides generally do not
consist of well defined three dimensional folds, but instead involve
basic residues in unstructured parts of effector proteins. Additionally,
PA can be metabolized to other lipids with potent bioactivity. For
instance, PA can be converted to diacylglycerol (DAG) by PA
phosphatases [38,39] and to lysophosphatidic acid (LPA), which has
an inverted cone shape and thus prefers positive curvature. Finally, PA
can serve as a precursor for other lipids in the biosynthetic pathway,
where it is consumed for the generation of lipids such as PI via the
CDP-DAG pathway. It should be noted that PLD is not the only source
Fig. 1. PLD structure, PAmetabolism and reactions catalyzed by PLD. (a) Structure of PLD isozymes. Structurally, the two isozymes differ by the presence of a loop domain in the PLD1
isozyme. (b) PA metabolism. Besides the PLD source, PA can be generated from other sources and further metabolized as represented in the figure. The dashed arrow represents the
biosynthetic pathway. The enzymes catalyzing the respective reactions are shown in red. (c) PLD activity. In the presence of water, PLD produces PA. In the presence of primary
alcohols, such as ethanol, PLD has a 1000-fold higher affinity for primary alcohols as nucleophiles, leading to a preferential generation of phosphatidylethanol (PEtOH). PLD,
Phospholipase D; PC, phosphatidylcholine; PA, phosphatidic acid; LPA, lyso-PA; DAG, diacylglycerol; CDP-DAG, cytidine diphosphate-DAG; PLA2, phospholipase A2; LPAAT, LPA
acyltransferase; PAP, PA phosphatase; DGK, DAG kinase; CDS, CDP-DAG synthase; mitoPLD, mito-phospholipase D.
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mitoPLD and other enzymes in the biosynthetic pathway [33,40]
(Fig. 1c). However, the fatty acyl composition of PA pools varies,
depending on the specific pathways mediating its production. For
example, PLD-derived PA species harbor mainly saturated or
monounsaturated fatty acids, rapidly giving rise to a pool of DAG
with the same properties (i.e., a cone shape), although the negative
charge of PA may confer distinct properties and allow for the binding
to a different set of effector proteins compared to DAG. In contrast, the
pool of DAG resulting from PI(4,5)P2 cleavage by PLC predominantly
harbors polyunsaturated fatty acids, likely achieving different phys-
iological functions [41,42].
While PLD1 localizes to the Golgi complex, secretory granules and
endosomes, PLD2 is concentrated at the plasma membrane, with
smaller pools present in theGolgi apparatus, caveolae and in endosomes
[43–46]. In part consistent with their subcellular localization, PLD1 has
been implicated in the budding and fusion of trans-Golgi-derived
secretory vesicles, whereas PLD2 mediates the internalization and
recycling of a variety of receptors. Importantly, PLD1 translocates to the
plasma membrane upon various stimuli and follows the endosomal
internalization route [32,34,47]. Our unpublished studies show that
PLD1 relocalizes to autophagosomes and modulates autophagy during
nutrient deprivation (Claudia Dall'Armi and GDP, unpublished
observations).
4. Role of the PLD pathway in brain function
Following the first description of mammalian brain-associated PLD
activity in 1973 [25], the same team reported the formation of ethanol
metabolite, PEtOH in rat brain synaptosomes through a PLD-mediated
transphosphatidylation reaction [48]. This method was further used
to measure PLD activity in homogenates of different brain regions,
where the hippocampus, hypothalamus and cortex were associated
with the highest PLD activity [49]. Both PLD1 and PLD2 are expressed
throughout the brain during development and postnatal life, although
levels of expression vary from one cell type to another, at least at the
mRNA level [30] (see also reference [50]). In agreement with these
expression patterns, both PLD1 and PLD2 have been implicated in
neurite outgrowth [51–53].PLD is likely to play a central role in neurophysiology based on its
abundance in the brain and on its implication in multiple aspects of cell
physiology including membrane trafficking, cytoskeleton regulation
and signal transduction [53–55]. Although no genetic or in vivo studies
support this idea at this time, several reports involving cell culture
models suggest this may be the case, particularly for PLD2. For instance,
a study utilizing both RNAi knockdown approach and primary alcohol
applicationhas shown thatPLD2, likely in concertwith smallGTPaseRal,
regulates the constitutive internalization of metabotropic glutamate
receptors, mGluR1a and mGluR5a, as well as colocalizes with these
receptors in theendocytic pathway [56].While this studypoints to a role
of PLD2 in the modulation of excitatory neurotransmission, growing
evidence suggests broader involvement in internalization processes.
Based on previous findings showing that opioid peptides stimulate PLD
activity in chicken embryo cultures [57], more recent studies have
shown that PLD regulates the trafficking of opioid receptors, such as the
μ- and δ-opioid receptors, with potentially important implications for
drug addiction [58,59]. In this case, however, PLD2 appears to be
required for ligand-induced (rather than constitutive) endocytosis and
to cooperate with the small GTPase Arf6 which plays an important role
in modulating vesicle trafficking to and from the plasma membrane
[60,61]. Interestingly, signalling processes downstream of PLD2 are
beginning to beunravelled, as PLD2-activatingopioidshavebeen shown
to lead to the production of reactive oxygen species (ROS) [62].
Collectively, these studies support a role for PLD2 in signalling processes
downstream of the opioid receptors as well as in the regulation of their
cell surface levels.
5. Links between PLD and Alzheimer's disease
The first study linking PLD to AD was published by Kanfer et al.
[63], where a decrease in PLD activity, as measured by an in vitro
choline release assay from radiolabeled PC, was first reported in AD
brain homogenates relative to those from control patients. However,
when PLD activity was re-investigated in AD brain homogenates
relative to those from demented patients without AD, no difference
was found [64]. The same group subsequently used PEtOH production
as a read-out for PLD activity in ethanol-incubated brain homogenates
and found an increase in PLD activity in AD brain extracts relative to
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increased protein levels of PLD1 were found in mitochondrial
fractions derived from AD brains, although the pathophysiological
significance of this finding is unclear [66]. In the next sections, we will
summarize more recent evidence connecting PLD to AD as well as to
the function of proteins, such as presenilins, which are involved in this
neurodegenerative disorder.
5.1. The role of PLD in the Aβ signaling pathway
Following the aforementioned in vitro studies with AD brain
homogenates, cell culture models were used to assess the impact of
APP overexpression and extracellular Aβ applications on PLD activity.
Overexpression of the neuronal isoform of human wild type APP in
P19 mouse embryonic cells caused an increase in PLD activity [67]. Aβ
application experiments were used as well with various peptide
preparation types. In LA-N-2 cells, a neuroblastoma cell line, an
increase in PLD activity was observed after incubating cells with
Aβ25–35, a peptide sequence whose pathophysiological significance
has been questioned [68]. Additionally, the same group showed that
indomethacin (a non-steroid anti-inflammatory drug), nordihydro-
guaiaretic acid (an anti-oxidant drug) and nicotine inhibited the
increase in PLD activity produced by Aβ25–35 applications [69,70].
Furthermore, alanine substitution for the amino acids on the positions
29–34 of Aβ25–35 prevented the peptide from having an effect on
PLD activity [71]. Finally, pre-treatment with Aβ25–35 desensitized
the cells, which did not exhibit a PLD activity increase in response to a
new Aβ25–35 treatment, thus prompting the authors to suggest that
Aβ25–35might mediate its effects on PLD upon receptor binding [70].
Aβ1–40 also produced an increase in PLD activity in rat hippocampal
primary cultures, but this effect was seen with high concentrations of
Aβ aged at 37 °C (likely reflecting a requirement for some aggregated
state of Aβ for this phenomenon to occur) [72]. The increase in PLD
activity induced by Aβ correlated with increased release of cytosolic
protein lactate dehydrogenase, suggesting it is associated with Aβ-
induced toxicity [72]. Besides neurons, Aβ1-42 used in the low
micromolar range caused an increase in PLD activity in astrocytes and
microglia in a process dependent upon formyl-peptide-receptor-like
1 (FPRL1). Specifically, Aβ1-42 was internalized alongside the FPRL1
receptor and stimulated a downstream signaling pathway involving
the phosphorylation of extracellular signal-regulated kinase (ERK).
Because both Aβ1-42 internalization and FPRL1-mediated signaling
were abrogated by a primary alcohol, a role for PLD in this process was
proposed [73]. Recently, our lab has addressed the effects of soluble
oligomeric preparations of Aβ1–42 (oAβ1–42), which are highly
synaptotoxic at submicromolar concentrations, on PLD activity. We
found that oAβ42 at 200 nM leads to an increase in PLD activity in
primary cortical cultures and that this effect is abolished in mouse
neurons lacking PLD2. Strikingly, we also found that the genetic
ablation of Pld2 confers protection against the suppressive effects of
oAβ1-42 on LTP and the memory-impairing action of SwAPP
overexpression in vivo (TGO and GDP, unpublished observations).
5.2. The role of PLD on APP trafficking and Aβ generation
Because Aβ originates from the sequential cleavage of APP by β-
and γ-secretases, tremendous effort has been put into attempting to
understand the molecular mechanisms regulating the subcellular
localization and intracellular sorting of APP and its cleaving enzymes,
all of which are transmembrane proteins or protein complexes.
Generally, an increasingly popular hypothesis in the field is that
perturbation of the trafficking of APP, BACE1 and γ-secretase complex
[including its catalytic components, presenilins (PS)] may profoundly
affect amyloidogenesis and thus impact AD pathogenesis [74].
As with most type 1 transmembrane proteins, APP traffics through
the secretory pathway toward the cell surface, where it can be re-internalized and reach the endosomal system. Additionally, there is
evidence that APP traffics back to the trans-Golgi network (TGN) and
it has been suggested that reducing this transport step results in
increased amyloidogenesis. This may reflect the fact that the APP/
BACE1 interaction is predominant in the endosomes and that the
acidic pH of this compartment is optimal for BACE1-mediated
proteolysis [74]. Despite the complexity in the intracellular trafficking
pattern of APP, most studies addressing the role of PLD in this process
have focused on the cell surface delivery of APP (and particularly, the
Swedish mutant of APP) from the TGN. These studies were prompted
by a large body of evidence implicating PLD1 as well as its product PA
in the budding of secretory vesicles from the TGN [75–77].
Furthermore, while the bulk of the studies addressing the relationship
between the γ-secretase complex and APP focus on the APP
processing, some evidence indicates that presenilin can also regulate
the trafficking of APP independently of its catalytic activity.
Specifically, TGN-derived secretory vesicles produced from PS1-
deficient cells contain higher levels of APP, thus resulting in increased
cell surface delivery of APP. The converse phenomenon was observed
in cells expressing an FAD mutant version of PS1 (i.e., ΔE9),
suggesting that these findings may be relevant for the pathogenesis
of AD [78]. Collectively, these results converged onto a transport
pathway involving APP, PS and PLD1, although evidence for a bona fide
crosstalk between these three molecules in the context of TGN-to-
plasmalemma traffic emerged in subsequent studies.
Accordingly, PLD1 overexpression was shown to promote the
formation of APP-containing secretory vesicles from TGN, thus
mimicking the effect of PSEN1 nullizygosity [79]. However, primary
alcohols failed to rescue this phenotype in PS1 knockout cells,
suggesting that the increased biogenesis of APP-containing vesicles
observed in PS1-deficient cells is PLD-independent. While these data
suggested that WT PS1 and PLD1 may regulate the traffic of APP
through independent pathways, there is a clear functional link
between these two proteins in the FAD mutant background (at
least, for the PS1ΔE9 mutant). For instance, a subcellular fractionation
experiment showed that expression of FAD PS1ΔE9 mutant in cells
leads to an enrichment of PLD1 in the Golgi/TGN fraction at the
expense of lighter fractions (which may in part represent endosomal
structures) and that this redistribution was concomitant with a
decrease in total PLD activity [79]. Importantly, overexpression of
catalytically active PLD1 (but not the lipase-dead mutant) was found
to rescue the defect in the budding of APP-containing vesicles from
the TGN as well in the cell surface delivery of APP induced by the PS1
ΔE9 [79].Whether PLD1 interacts with APP or not is amatter of debate
as conflicting data were obtained in independent studies [66,80].
While the aforementioned study highlights the effects of PLD1 on
APP trafficking, Cai et al. [81] also addressed the role of PLD1 in
amyloidogenesis. First, it was shown that PLD1 (but not PLD2)
physically interacts with the cytoplasmic loop region of PS1 and that
through this binding PS1 mediates the recruitment of PLD1 to the
Golgi complex. Furthermore, in N2a cells expressing the PS1 mutant
ΔE9, overexpression of PLD1 decreased the levels of Aβ, whereas
silencing PLD1 and expression of a lipase-dead PLD1mutant produced
the converse effect. Interestingly, co-precipitation experiments
showed that PLD1 regulates the assembly of the γ-secretase complex
through a direct effect on PS1 (but not the other components of the
complex: Pen-2, nicastrin and APH1), although this phenomenon
appears to be independent of the lipase activity of PLD1.
Since PLD1 regulates the traffic of APP and that APP, in turn, may
affect the transport of PS1, it was hypothesized that PLD1 could
regulate the trafficking of PS1 indirectly, through APP. However,
recently published evidence has suggested that PLD1 positively
regulates the delivery of PS1 to the cell surface in an APP-independent
fashion [80]. Indeed, analysis of PS1 localization in mouse embryonic
fibroblasts (MEFs) lacking both APP and its related family member
APP-like-protein 2 (APLP2) (APP dKO) showed increased cell surface
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expression of catalytically-active PLD1, but it also occurred in APPdKO
cells, thus suggesting that it is independent of an effect of PLD1 on APP
transport [80].
In summary, there appears to be a significant crosstalk between
PLD1, APP and PS1 with important implications for amyloidogenesis.
However, it is unclear whether this crosstalk also occurs in vivo,
which should be best addressed with genetic models. Importantly,
PLD1 and PLD2 are likely to play distinct roles in AD pathogenesis,
perhaps reflecting their differential subcellular localization, expres-
sion levels/profile, and regulation as well as their ability to control
different aspects in the biology of the key proteins involved in AD.
6. Other potential links between PLD and neurodegeneration
There are at least four additional lines of research potentially
linking PLD to degenerative processes. The first involves PLD and a
potential link with α-synuclein; the second implicates PLD isozymes
as substrates of caspases; the third points to how a perturbation of PA
metabolism can alter membrane dynamics with consequences on cell
viability; and the fourth involves the connection between PLD and
mTOR in survival pathways.
6.1. PLD and Parkinson's disease
In addition to regulating the function of a variety of receptors, PLD
has been implicated in brain-associated pathophysiology through an
interaction with a disease-relevant cytoplasmic protein, α-synuclein.
This aggregate-prone protein is the product of a gene that is mutated
in familial cases of Parkinson's disease (PD) and also involved in AD
pathology based on its presence in Lewy bodies and neuritic plaques,
respectively [82]. The original study suggesting a functional link
between α-synuclein and PLD2 demonstrated that α-synuclein
inhibits the lipase activity of PLD2 in vitro [83]. Subsequent studies
have corroborated this link through analyses of the direct physical
interaction between these two proteins and of the effects of various
PD-linked mutations on PLD activity both in vitro and in intact cells
[84,85]. However the (patho)physiological relevance of this interac-
tion has been questioned, since conflicting data has been obtained by
others with respect to the inhibitory action of α-synuclein on PLD
activity [86].
6.2. PLD and programmed cell death
Two recent studies have shown that caspases-8, -3 and -7 can
cleave PLD isozymes in vitro [87] and that caspase-3 can also cleave
these enzymes in vivo [88]. Both demonstrate that PLD1 is cleaved
within its loop, which is a region that structurally distinguishes PLD1
from PLD2 and negatively regulates the lipase activity of PLD1. This
caspase cleavage produces two fragments of approximately 60 (NH2-
terminus) and 55 kDa (at the COOH-terminus), respectively. In
contrast, PLD2 is cleaved in proximity to the NH2-terminus, resulting
in a shift in PLD2's molecular weight from 106 to 102 kDa with a
release of a small fragment and a larger one still encompassing the
bulk of the PLD2 sequence. However, these studies present conflicting
conclusions concerning the impact on the activity of the enzymes
after caspase-induced cleavage and the role of the various proteolytic
products in the modulation of apoptosis outcome [87,88]. For
instance, the first study shows that caspase-cleaved PLD1 was no
longer activated by PKC, but resulted in increased activity induced by
small GTPases, and PLD2 activity did not change after caspase-3
induced cleavage [87]. However, the second study shows that
apoptosis-induced PLD1 cleavage results in lower PLD1 activity levels
and agrees with in vitro studies demonstrating that apoptosis-induced
PLD2 cleavage had no effect on its activity [88]. Regardless of this
discrepancy, caspase-mediated cleavage of PLD may be relevant forAD, as these proteases have been extensively implicated in this
disorder (e.g., downstream of Aβ) [89] and both caspase-3 activity
and PLD1 fragments matching the size of those generated by caspase-
3 are upregulated in AD brain tissue [88].
6.3. PLD overexpression and cellular degeneration
A recent report by Raghu et al. [90] provided further insight into the
role of PLD in neurodegeneration. In Drosophila melanogaster photo-
receptors, PA levels were altered using distinct genetic manipulations
targetingPAmetabolism, suchas (i) overexpressionof the only Pld gene;
(ii) partial inactivation of cytidine diphosphate (CDP)-DAG synthase
(i.e., cds1), which consumes PA for the de novo production of other
phospholipids; and (iii) overexpression of rdgA, a gene encoding a fly
DAG kinase. These three genetic manipulations produced major
developmental defects in the photoreceptors, specifically with reduc-
tion in the size of rhabdomeres, a specialized structure in these
photoreceptors where sensory transduction occurs. Remarkably, this
phenotype correlatedwith increased levels of a singlemolecular species
of PA (out of 17 analyzed) with a specific fatty acyl composition—34:2
(16:0/18:2 or 16:1/18:1) and was rescued by co-expression of a PA
phosphatase. This study underscores the physiological importance of
regulating metabolic pools of PA, and suggests that certain cells, tissues
or organisms may not efficiently cope with increased PLD levels/
activity, a situation proposed to occur in AD.
6.4. PLD and the mTOR pathway
In the past few years, several studies have highlighted a role for PLD
in cell survival. For instance, increased PLD activity was correlated with
enhanced survival rates in various human cancer tissues and neoplastic
cell lines and also, numerous growth factors have been shown to lead to
increased PLD activity [91]. These findings may be related to the
observation that PLD can regulate mTOR (mammalian target of
rapamycin), which is involved in cell growth and proliferation and has
also been proposed to play a role in AD [91,92]. mTOR is present in two
complexes, mTORC1 (when mTOR is bound to Raptor) and mTORC2
(when bound to Rictor). Rapamycin inhibits the formation of the
mTORC1 complex through an interactionwith FKBP12 (i.e., amodulator
of the activity of various complexes in the cell). Interestingly, PA was
found to compete with rapamycin for binding to the FRB domain of
mTOR [93]. Moreover, PAwas shown to be required for the stabilization
of mTORC1 and 2 complexes, competing with rapamycin [94].
Additionally, PLD1, but not PLD2, was shown to be required for the
activation of mTOR by Rheb [95]. Even though the majority of the data
suggests a stronger role for PLD1, there is conflictingdata concerning the
specific role of how each PLD isozyme affects mTOR regulation [96].
7. Conclusions and future directions
Here we review an increasing number of reports showing the
involvement of PLD in AD pathogenesis. Although PLD1 and PLD2
have similar protein structures (with the exception of the regulatory
loop) and catalyze the same reaction, their different regulation and
localization in the cell, implicate these proteins in different cellular
processes. In the case of AD pathogenesis, several studies point to a
role of PLD1 in the intracellular trafficking of APP and presenilin with
important implications for amyloidogenesis. Although PLD2 has not
been extensively studied in the context of AD, our unpublished work
suggests it may regulate processes associated with Aβ signaling,
perhaps due to its predominant localization at the cell surface, a main
site of action of this cytotoxic peptide. Importantly, ablation of PLD2
appears to be protective in the context of a transgenic model of AD.
Whether PLD has any role in AD-associated tau pathology remains to
be discovered. However, the pleiotropic actions of PLD isozymes in the
cell, including their implication in many signal transduction pathways,
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appears to be hyperphosphorylation of microtubule-associated protein
by such kinases as CDK5 and GSK3β, thus denoting a profound
dysregulation of signaling pathways. Interestingly, a link between PLD
and these two kinases has been recently published [97,98]. Further-
more, the implication of PLD in the mTOR pathway, combined with an
increasing number of studies exploiting inhibitors of this pathway (e.g.,
rapamycin analogs) to treat proteinopathies as a result of their
stimulatory actions on the macroautophagy pathway, suggests that a
manipulation of PLD is likely to affect the clearance of protein
aggregates.
PLD isozymes are ubiquitously expressed lipid enzymes implicated
in multiple facets of cell physiology, consistent with the pleiotropic
roles of their product, PA. Despite nearly two decades of research on
these proteins, their physiological (in vivo) functions are still elusive,
in part due to the lack of genetic tools in mammalian systems. While
efforts along this line are ongoing in several laboratories (including
our own), work in lower species suggests that PLD-encoding genes are
largely non-essential, unless organisms are undergoing some stress
conditions [99]. In this respect, while the discovery that PLD genes are
non-essential in mammals contrasts the many studies implicating
PLD1 and PLD2 in fundamental cellular processes, it suggests the
exciting possibility that PLD isozymes may be used as potential drug
targets for therapeutics in several areas, including AD and cancer. The
recently generated pharmacological blockers of these enzymes may
prove extremely helpful in this endeavor, particularly if they have
different efficacies toward the two isozymes [100–102].
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